Article Text

Download PDFPDF

103 Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
  1. I Parodis1,
  2. C Sjöwall2,
  3. A Jönsen3,
  4. D Ramsköld1,
  5. A Zickert1,
  6. M Frodlund2,
  7. A Sohrabian4,
  8. L Arnaud5,
  9. J Rönnelid4,
  10. V Malmström1,
  11. AA Bengtsson3 and
  12. I Gunnarsson1
  1. 1Karolinska Institutet, Department of Medicine- Rheumatology Unit, Stockholm, Sweden
  2. 2Linköping University, Department of Clinical and Experimental Medicine- Rheumatology/AIR, Linköping, Sweden
  3. 3Lund University, Department of Clinical Sciences Lund- Rheumatology, Lund, Sweden
  4. 4Uppsala University, Department of Immunology- Genetics and Pathology, Uppsala, Sweden
  5. 5Hôpitaux Universitaires de Strasbourg, Service de Rhumatologie- Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares, Strasbourg, France


Background and aims Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings.

Methods Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53 months. Surveillance outcomes included the SLE Disease Activity Index 2000 (SLEDAI-2K), 100 mm Visual Analogue Scales for Physician’s Global Assessment (PGA), fatigue, pain and general health, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Assessment of treatment response included the SLE responder index (SRI). B lymphocyte stimulator (BLyS) levels were determined using ELISA.

Results SLEDAI-2K (median baseline score: 8.0; IQR: 4.0–13.8), PGA and corticosteroid use decreased during therapy, and patients reported improvements on fatigue, pain, and general health (p<0.0001 for all). SDI scores remained stable (p=0.08). Patients with baseline SDI scores>1 showed decreased probability and prolonged time to attain SRI response (HR: 0.449; 95% CI: 0.208–0.967), as did current smokers compared with non-smokers (HR: 0.103; 95% CI: 0.025–0.427). In contrast, baseline BLyS levels≥1.2 ng/mL predicted increased probability and shorter time to attain SRI response (HR: 2.566; 95% CI: 1.222–5.387).

Conclusions Disease activity and corticosteroid usage decreased, patient-reported outcomes improved, and no significant organ damage was accrued during follow-up. Smoking and organ damage predicted reduced treatment efficacy. These findings might contribute to a better selection of patients who are likely to benefit from belimumab.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.